HMMR and cancer: Only N+ tumours with the RHAMM+/TIL− phenotype demonstrated a significantly worse prognosis (P=0.005), with 5-year cancer-specific survival rate of 15% (95% CI 6–28%), compared with N0 tumours with the adverse RHAMM+/TIL− phenotype (the 5-year survival rate: 53% (95% CI 35–69%)).